Skip to content
ePORE Therapy Logo
  • About Mirai
  • Technology
    • What is Electroporation?
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Skin Therapy
    • Clinicians
    • Patient Information
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • News
  • References
  • Contact
Menu
  • About Mirai
  • Technology
    • What is Electroporation?
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Skin Therapy
    • Clinicians
    • Patient Information
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • News
  • References
  • Contact

Author: admin

Filter by Topic
Galway-based Mirai Medical raises €3m in funding
Read More
25.03.2021
Endoscopic electrochemotherapy for Oesophageal cancer: a phase I clinical study
Read More
25.03.2021
Phase one Study on electrochemotherapy for colorectal cancer using endoscopic electroporation
Read More
25.03.2021

Contact Us

By clicking send, you confirm you have read and agreed to Mirai Medical's Privacy Policy.
Twitter Linkedin-in Youtube
ePORE Therapy White Logo
Address:
Mirai Medical
Unit 5, Howley Court
Oranmore
Galway
Ireland
Email:
info@mirai-medical.com
Mirai Medical logo white
Dynamic Meta widget allowed only for Posts listing source or in Post context
Privacy & Cookies
ePORE® therapy, EndoVE® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE® therapy, EndoVE® and CUTIS are not cleared by FDA for commercialisation in the USA.
Website by Proactive Design & Marketing